Milan, Italy (January 10, 2023)
Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced the new composition of the Board of Directors.
The company confirmed Marco Ferroni as MgShell President and Chairman of the Board, maintaining his operative role as Chief Executive Officer. Francesco De Gaetano was confirmed as Board Member and Chief Technology Officer, as well. Enrico Gianotti also serves as Board Member in the position previously held by Federica Boschetti, the company’s co-founder and current Scientific Advisor. The company expresses its gratitude to Federica Boschetti for her work within the Board of Directors.
Enrico Gianotti, graduated at Politecnico di Torino and MBA at ESCP-EAP School, is currently the CEO and co-founder of PE Industrial srl, a company focused on investments in industrial SMEs, ScaleUp, and Start Up, through acquisitions and operational partnerships. In conclusion, the company announces that Stefano Gallucci and Marco Gullà, representing the investor shareholders, will support the work of the board of directors in the role of observers.
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
